| Assay Prediction |
Pathology |
Clinical Features |
| Tissue of Origin |
Veridex |
Histology |
IHC |
Age/Sex |
Sites of Metastasis |
Response to Treatment |
Survival (mo) |
| Pancreas |
Pancreas |
Adenocarcinoma |
None |
50/F |
lung, liver, spleen |
PD |
5 |
| Pancreas |
Pancreas |
Adenocarcinoma |
CK7+, CK20+ |
64/F |
abdominal soft tissue, liver |
SD |
6 |
| Pancreas |
Pancreas |
PD adenocarcinoma |
None |
52/M |
Liver, lung, lymph nodes |
PR |
11 |
| Pancreas |
Pancreas |
Adenocarcioma |
CEA+, Moc31 (EpCAM)+, B723+, HepPar1- |
56/F |
Lung, GE junction, liver, bone, lymph nodes |
SD |
7 |
| Pancreas |
Colon |
PD adenocarcinoma |
None |
44/F |
Liver, peritoneum, pancreas |
NE |
1 |
| Pancreas |
Other |
PD carcinoma |
CK7+, CK20-, AFP- |
35/M |
Liver, omentum |
PD |
2 |
| Colorectal |
Pancreas |
Adenocarcinoma |
CK7+, CK20-, CA125-, TTF1-, CEA- |
66/F |
Liver |
NE |
4 |
| NSCLC |
Pancreas |
PD adenocarcinoma |
None |
65/M |
Lung, lymph nodes, abdominal wall |
NE |
<1 |
| NSCLC |
Pancreas |
PD adenocarcinoma |
None |
44/F |
Lymph nodes |
PR |
21 |
|
